insulin detemir + oral antidiabetic drugs

This agent is a **combination regimen** consisting of the insulin analog **insulin detemir**, a long-acting basal insulin, plus one or more oral antidiabetic drug(s) (OADs). - **Insulin detemir** acts via the insulin receptor to promote glucose uptake and inhibit hepatic glucose output, providing sustained basal insulin levels. It differs from native human insulin by a fatty acid (myristic acid) chain that facilitates reversible binding to albumin, thus prolonging its action. - **Oral antidiabetic drugs** in this context may include metformin (biguanide), sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, or alpha-glucosidase inhibitors, each with distinct mechanisms for improving glycemic control. - The combination is **used for patients with type 2 diabetes mellitus inadequately controlled on OADs**, providing significantly improved glycemic control, reduced HbA1c, lower fasting and postprandial plasma glucose, with a low risk of hypoglycemia and minimal weight gain compared to other insulins[1][2][4]. - Approved insulin detemir products include Levemir, Levemir FlexPen, and Levemir FlexTouch[3].